Advertisement

Topics

Bone Metastasis - Pipeline Review, H1 2015

01:13 EDT 15 Apr 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Bone Metastasis - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-03-10. This 107-page report is available in PDF from $2000.

Bone Metastasis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Bone Metastasis - Pipeline Review, H1 2015’, provides an overview of the Bone Metastasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bone Metastasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Bone Metastasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Bone Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bone Metastasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of…

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Bone Metastasis Overview 9
Therapeutics Development 10
Pipeline Products for Bone Metastasis - Overview 10
Pipeline Products for Bone Metastasis - Comparative Analysis 11
Bone Metastasis - Therapeutics under Development by Companies 12
Bone Metastasis - Therapeutics under Investigation by Universities/Institutes 14
Bone Metastasis - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Bone Metastasis - Products under Development by Companies 18
Bone Metastasis - Products under Investigation by Universities/Institutes 20
Bone Metastasis - Companies Involved in Therapeutics Development 21
Ablynx NV 21
Alethia Biotherapeutics Inc. 22
Amgen Inc. 23
Amura Holdings Ltd. 24
Bayer AG 25
ChemoCentryx, Inc. 26
Debiopharm International S.A. 27
Deciphera Pharmaceuticals, LLC 28
Digna Biotech, S.L. 29
Medivir AB 30
Merrion Pharmaceuticals Plc 31
Osteologix Holdings Plc. 32
R-Pharm 33
Sigma-Tau S.p.A. 34
Bone Metastasis - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
AB-25E9 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ADM-01 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
alendronate sodium + HPMA + paclitaxel - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
alendronate sodium + paclitaxel + PEG - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ALX-0141 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
AM-3701 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
AMG-161 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
CCX-721 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
DCC-2909 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
DCC-3014 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Debio-0719 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
denosumab - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
disitertide - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Drugs to Inhibit…

For more information open Bone Metastasis - Pipeline Review, H1 2015.

SKU: GMDHC6262IDB

Original Article: Bone Metastasis - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Bone Metastasis - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...